Detail akcie Neuren Pharma online

Business Summary: Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Neuren Pharmaceuticals Ltd revenues decreased 97% to A$389K. Net loss totaled A$10.8M vs. income of A$3.1M. Revenues reflect Revenue from licence agreement decrease from A$13.5M to A$0K. Net loss reflects Research and development costs increase of 62% to A$9.9M (expense), Foreign exchange gain decrease of 86% to A$132K (income).